Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

Was Kymera Therapeutics Inc (KYMR)'s session last reading good? – US Post News - US Post News

US Post News

Kymera Therapeutics Inc (KYMR) Stock: Navigating Drops and Gains - The InvestChronicle

The InvestChronicle

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5% - MarketBeat

MarketBeat

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire Inc.

NEOsphere, Kymera Therapeutics Collaborate on Novel Molecular Glue Target Discovery - Contract Pharma

Contract Pharma

Neosphere Biotechnologies and Kymera Therapeutics partner to advance molecular glue target discovery - BioWorld Online

BioWorld Online

Kymera Therapeutics stock target cut, keeps neutral rating on Q1 results - Investing.com Canada

Investing.com Canada

(KYMR) On The My Stocks Page - Stock Traders Daily

Stock Traders Daily

Kymera Therapeutics (KYMR) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo News UK

Yahoo News UK

Kymera Therapeutics to Participate in Upcoming May Investor Conferences - Investing.com South Africa

Investing.com South Africa

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand - Yahoo Finance

Yahoo Finance

Kymera Therapeutics (NASDAQ:KYMR) PT Lowered to $52.00 - Defense World

Defense World

Kymera Therapeutics (NASDAQ:KYMR) PT Lowered to $52.00 - Defense World

Defense World

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

Zacks Investment Research

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance

Yahoo Finance

Earnings call: Kymera Therapeutics reports progress in drug development - Investing.com

Investing.com

Earnings call: Kymera Therapeutics reports progress in drug development - Investing.com

Investing.com

All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy - Yahoo New Zealand News

Yahoo New Zealand News

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research

Zacks Investment Research

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks Investment Research

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

Zacks Investment Research

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know - Nasdaq

Nasdaq

Earnings call: Kymera Therapeutics reports progress in drug development - Investing.com

Investing.com

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth - Simply Wall St

Simply Wall St

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire Inc.

Kymera Therapeutics (NASDAQ:KYMR) Shares Up 6.8% - MarketBeat

MarketBeat

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update - 02.05.2024 - wallstreet:online

wallstreet:online

Kymera Therapeutics Inc (KYMR) Becoming More Attractive for Investors – Knox Daily - Knox Daily

Knox Daily

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance

Yahoo Finance

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Benzinga

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Kymera Therapeutics (NASDA - Benzinga

Benzinga

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire Inc.

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - Seeking Alpha

Seeking Alpha

Kymera Therapeutics moves to Arsenal on the Charles in Watertown - The Business Journals

The Business Journals

Kymera Therapeutics discovers new CDK2 degradation inducers for cancer - BioWorld Online

BioWorld Online

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

GlobeNewswire Inc.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire Inc.

Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know

Benzinga

Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know - Markets Insider

Markets Insider

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance

Yahoo Finance

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views

Benzinga

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire Inc.

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results - Yahoo Finance

Yahoo Finance

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

GlobeNewswire Inc.

Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc - Yahoo Finance

Yahoo Finance